FTC Affiliate Disclosure: This article may contain affiliate links. If you enroll through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or integrity of the information presented.
For consumers who are interested in GLP-1 weight loss medications but want to avoid weekly injections, 2026 has introduced a confusing landscape. There are now FDA-approved oral GLP-1 options, compounded oral formulations, and sublingual preparations — and these are not equivalent products, even when they contain similar active ingredients.
Understanding why these formats differ requires some pharmacology. This article covers the absorption science in consumer-accessible terms, explains what the FDA approval of oral Wegovy actually means for the market, and addresses the legal and scientific questions surrounding compounded oral GLP-1 products.
Why Oral GLP-1 Delivery Is Pharmacologically Difficult
GLP-1 receptor agonists like semaglutide and tirzepatide are large peptide molecules. Peptides are chains of amino acids — the same building blocks that make up proteins. When you swallow a peptide, your digestive system does exactly what it is designed to do: it breaks it down.
Stomach acid denatures the peptide structure. Digestive enzymes — particularly pepsin in the stomach and proteases in the small intestine — cleave the amino acid chains into fragments that no longer function as GLP-1 agonists. The intestinal lining, designed to absorb small nutrients, presents an additional barrier to large intact molecules.
This is why the vast majority of GLP-1 medications have historically been administered by injection — bypassing the digestive system entirely and delivering the active molecule directly into subcutaneous tissue where it can reach the bloodstream intact.
How Rybelsus Solved the Problem — and Why It Matters
Novo Nordisk's Rybelsus (oral semaglutide for type 2 diabetes) was the first GLP-1 agonist to achieve FDA approval in oral tablet form. The solution involved a specialized co-formulated absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate).
SNAC works by temporarily raising the local pH in the stomach lining and facilitating transcellular absorption of semaglutide across the gastric epithelium. Even with this technology, the bioavailability of oral semaglutide is approximately 1 percent — meaning 99 percent of the active ingredient is lost to degradation before reaching systemic circulation.
To compensate for this low bioavailability, oral semaglutide tablets contain substantially higher doses of the active ingredient than injectable formulations. The tablets must also be taken under specific conditions — on an empty stomach, with no more than 4 ounces of plain water, followed by a 30-minute fasting window before eating or taking other medications.
In December 2025, the FDA approved an oral version of Wegovy (semaglutide tablets for weight loss) using the same SNAC-based technology. This was a significant milestone — the first FDA-approved oral GLP-1 specifically indicated for weight management.
The Compounded Oral GLP-1 Question
Alongside the FDA-approved oral options, several telehealth platforms have offered compounded oral tablets or sublingual formulations of semaglutide or tirzepatide. These compounded GLP-1 products are prepared by compounding pharmacies and do not use the patented SNAC absorption technology.
This raises a fundamental pharmacological question: how does a compounded oral GLP-1 tablet achieve therapeutic absorption without a specialized delivery system?
A class-action complaint filed in November 2025 against compounding pharmacy Triad Rx and telehealth infrastructure provider OpenLoop alleged that compounded oral tirzepatide tablets had “no demonstrated mechanism of absorption or efficacy.” The complaint cited the pharmacological challenges described above — tirzepatide is a large peptide that digestive enzymes destroy before it can reach the bloodstream — and noted that no published clinical data demonstrates that compounded oral tirzepatide achieves therapeutic levels without absorption-enhancing technology comparable to SNAC.
This is an allegation in pending litigation, not a proven finding. However, the underlying pharmacological question is scientifically grounded. No published peer-reviewed study currently demonstrates that compounded oral tirzepatide tablets achieve blood levels sufficient for therapeutic effect without a specialized absorption mechanism.
Consumers considering oral GLP-1 options from any provider should discuss absorption and bioavailability questions directly with their prescribing clinician.
Sublingual Delivery: A Different Approach
Some compounded formulations are designed for sublingual delivery — placed under the tongue rather than swallowed. Sublingual administration is an established pharmaceutical delivery method with published research supporting faster absorption for certain medications.
The sublingual route bypasses gastric degradation by allowing the active ingredient to absorb directly through the mucous membrane under the tongue into the bloodstream. This approach has documented effectiveness for small molecules and certain peptide formulations.
Whether sublingual delivery achieves therapeutic absorption for specific compounded GLP-1 or multi-ingredient formulations depends on the specific compounds, concentrations, and formulation characteristics. The evidence base for sublingual delivery varies by active ingredient and combination. Some telehealth platforms in adjacent categories — such as compounded erectile dysfunction treatments — use sublingual delivery as their primary format. For analysis of one such product line and how sublingual delivery applies in the compounded ED context, see our compounded ED telehealth report.
Comparing Your Options in 2026
For consumers specifically seeking needle-free GLP-1 options, the practical landscape in 2026 includes three categories with very different evidence bases and regulatory profiles.
FDA-approved oral options — Rybelsus and oral Wegovy — have completed clinical trials, use patented absorption technology, and carry FDA approval for their specific indications. They are the most evidence-supported oral GLP-1 path available, though they cost significantly more than compounded alternatives and require specific administration protocols.
Compounded oral GLP-1 tablets from telehealth platforms offer lower pricing but face the unresolved absorption question described above. Until published clinical data addresses whether these compounded GLP-1 formulations achieve therapeutic blood levels, consumers are navigating scientific uncertainty.
Compounded sublingual formulations use a different delivery mechanism that avoids gastric degradation. The evidence base for sublingual GLP-1 delivery is more established than for oral tablet delivery, though the specific compounded formulations available through telehealth platforms have not been individually studied as finished products.
MEDVi is among the telehealth platforms that have offered multiple GLP-1 formats. For broader context on the company's regulatory situation, growth story, and product categories, see our full MEDVi report. For guidance on how to evaluate any provider's credentials, see our verification checklist.
Consumers considering any oral or sublingual GLP-1 option should discuss the specific formulation's absorption mechanism with their prescribing clinician before enrolling. Your healthcare provider can help evaluate whether the delivery format is likely to be effective for your specific situation.
This analysis was compiled from published pharmacological research, FDA approval records, court filings, and verified industry reporting. HealthDataConsortium.org is committed to data-driven health reporting and does not provide medical advice. Individual results with any weight management program vary. Always consult a licensed healthcare professional before starting any medication.
HealthDataConsortium.org Editorial Team | Published April 2026